This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.

Inclusion Criteria:

• Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects or those already receiving other anti-diabetic medications including GLP-1 analogues other than Liraglutide, who require treatment with liraglutide according to the clinical judgment of their treating physician
• Subjects who are capable of giving study-specific signed informed consent before any collection of information

Exclusion Criteria:

• Subjects with type 1 diabetes
• Subjects who are or have previously been on liraglutide
• Subjects who are participating in another clinical trial
• Subjects with a hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections)
• Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the following 6 months

Adult subjects with type 2 diabetes, including newly-diagnosed subjects or those already receiving other anti-diabetic medications including GLP-1 analogues other than liraglutide.